NasdaqGS:BIIBBiotechs
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors
On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleotide (ASO) platform to develop antisense therapeutics against multiple undisclosed RNA targets, with Alloy receiving an upfront payment plus potential milestones and tiered royalties.
A key angle for investors is that this deal pairs Biogen’s neurological drug development expertise with a next-generation ASO platform specifically...